CLDX - Celldex Therapeutics, Inc.
IEX Last Trade
25.13
-16.710 -66.494%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$41.84
-16.71
-39.94%
Fundamental analysis
10%
Profitability
0%
Dept financing
2%
Liquidity
75%
Performance
5%
Performance
5 Days
-0.04%
1 Month
-10.70%
3 Months
-30.23%
6 Months
-30.60%
1 Year
-36.35%
2 Year
-43.03%
Key data
Stock price
$25.13
DAY RANGE
$24.49 - $41.84
52 WEEK RANGE
$23.76 - $53.18
52 WEEK CHANGE
-$38.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Anthony S. Marucci
Region: US
Website: celldex.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: celldex.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Celldex Therapeutics, Inc. engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27.
Recent news